Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Publication Date timeline is not available.
Page 1
Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.
Cancer Immunol Immunother. 2008 Sep;57(9):1357-65. doi: 10.1007/s00262-008-0471-z. Epub 2008 Feb 12.
Cancer Immunol Immunother. 2008.
PMID: 18265979
Free PMC article.
Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Neeley YC, McDonagh KT, Overwijk WW, Restifo NP, Sanda MG.
Neeley YC, et al.
Prostate. 2002 Nov 1;53(3):183-91. doi: 10.1002/pros.10136.
Prostate. 2002.
PMID: 12386918
Free PMC article.
Item in Clipboard
Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG.
Neeley YC, et al.
Prostate. 2008 May 15;68(7):715-27. doi: 10.1002/pros.20689.
Prostate. 2008.
PMID: 18302222
Free article.
Item in Clipboard
A safety-modified SV40 Tag developed for human cancer immunotherapy.
Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, Sanda MG.
Tseng-Rogenski SS, et al. Among authors: neeley yc.
Drug Des Devel Ther. 2009 Feb 6;2:17-24.
Drug Des Devel Ther. 2009.
PMID: 19920890
Free PMC article.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.